Analyses of pivotal study data of Dysport® reveal a large proportion of study patients did not require retreatment for at least 12 weeks This new analysis.
By Natalie Grover LONDON (Reuters) - Alzheimer's disease experts in Europe weighing potential use of a new drug from Eisai and Biogen say its ability .
Alzheimer's disease experts in Europe weighing potential use of a new drug from Eisai and Biogen say its ability to slow cognitive decline may not outweigh its health risks, or be worth the toll on scarce healthcare resources.
European Alzheimer s experts unconvinced by new Eisai, Biogen drug – The Frontier Post thefrontierpost.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thefrontierpost.com Daily Mail and Mail on Sunday newspapers.
Colour are throwing their first ever 24-hour, two-level party beat.com.au - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from beat.com.au Daily Mail and Mail on Sunday newspapers.